Compared to the BPDCN groups, non-BPDCN-type CD56+ neoplasm cases showed higher cytoplasmic CD3 positivity and less frequent BCL-2 expression, and absence of cutaneous lesions. This evidence concerns the gene NCAM1 and neoplasm.